Hema Now: Innovation, Access, and Leadership in Cellular Therapy

In this episode of Hema Now, Megan Melody speaks about the evolution of CAR-T cell therapy and its impact on lymphoma care. She explores the major advances that have transformed outcomes for patients with relapsed and refractory disease, the unanswered questions shaping current research, and the practical challenges of building successful cellular therapy programmes. The conversation also covers equitable access to treatment, the role of quality standards and accreditation, personalised approaches to CAR-T therapy, and the importance of physician leadership and mentorship in shaping the future of academic haematology. Timestamps:   00:00 – Introduction   01:13 – Journey into Haematology and Lymphoma   04:19 – Major Advances in CAR-T   06:00 – Unanswered Questions After CAR-T   07:45 – Building Successful Cellular Therapy Programmes   09:06 – Improving Access to CAR-T   12:55 – Evolving Standards in Cellular Therapy   14:16 – Towards Personalised CAR-T Treatment   16:00 – Physician Leadership in Academic Medicine   17:10 – Career Advice for Future Specialists   19:02 – Future Directions in Cellular Therapy